The August 10, 2017 issue of the New England Journal of Medicine included a research article on "Influenza Vaccine Effectiveness in the United States during the 2015-16 Season".  This article reported the results from the U.S. Flu VE (Vaccine Effectiveness) Network demonstrating that the live attenuated vaccine (FluMist) was not effective in children.  The estimated vaccine effectiveness was only 5% for FluMist compared to 60% for inactivated vaccine in children.  The overall vaccine effectiveness was 53% against the H1N1 strain.  The study included about 6,900 participants with acute respiratory illness, including 1,216 who were enrolled at the Marshfield Clinic.  The study findings were presented to the CDC Advisory Committee on Immunization Practices (ACIP) in 2016, and they contributed to the decision to not recommend FluMist use in 2016-17 or 2017-18.  The U.S. Flu VE Network is funded by the CDC (Centers for Disease Control and Prevention) and includes the Marshfield Clinic Research Institute, University of Michigan, University of Pittsburgh, Baylor Scott and White, and Kaiser Washington.  Marshfield coauthors on the New England Journal paper were Ed Belongia, MD and Huong McLean, PhD, MPH